HLA Class I Histocompatibility Antigen, alpha Chain E (HLAE) antibody

Details for Product No. ABIN94356
Antigen
Reactivity
Human
130
8
7
6
6
2
2
1
1
Host
Mouse
66
65
Clonality (Clone)
Monoclonal ()
Conjugate
Un-conjugated
12
4
4
3
3
3
3
3
3
3
2
2
1
1
1
1
1
Application
Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunoprecipitation (IP)
70
41
32
24
24
20
13
2
2
1
Options
Immunogen Bacterially expressed recombinant HLA-E refolded with beta2-microglobulin and peptide.
Clone MEM-E-07
Isotype IgG1
Specificity The antibody MEM-E/07 recognized native surface-expressed HLA-E, but not denaturated heavy chain of HLA-E. HLA-E belongs to the MHC Class I molecules (MHC Class Ib, nonclassical) and it is expressed on many types of the human cells.
The published results revealed that the antibody cross-reacts with some classical MHC Class I molecules (MHC Class Ia): HLA-B7 (strongly), HLA-B8 (moderately), HLA-B27, -B44 (weakly).
Cross-Reactivity (Details) Human
Purification Purified by protein-A affinity chromatography
Purity > 95 % (by SDS-PAGE)
Antigen
Alternative Name HLA-E (HLAE Antibody Abstract)
Pathways Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Human Leukocyte Antigen (HLA) in Adaptive Immune Response
Application Notes Optimal working dilution should be determined by the investigator.
Restrictions For Research Use only
Concentration 1 mg/mL
Buffer Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Preservative Sodium azide
Precaution of Use This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Do not freeze.
Storage 4 °C
Storage Comment Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Supplier Images
Image no. 1 for anti-HLA Class I Histocompatibility Antigen, alpha Chain E (HLAE) antibody (ABIN94356) Immunohistochemistry staining of human spleen (paraffin sections) with anti-HLA-E (cl...
Product cited in: Nachmani, Zimmermann, Oiknine Djian, Weisblum, Livneh, Khanh Le, Galun, Horejsi, Isakov, Shomron, Wolf, Hengel, Mandelboim: "MicroRNA editing facilitates immune elimination of HCMV infected cells." in: PLoS pathogens, Vol. 10, Issue 2, pp. e1003963, 2014 (PubMed).

Allard, Oger, Vignard, Percier, Fregni, Périer, Caignard, Charreau, Bernardeau, Khammari, Dréno, Gervois: "Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer." in: PLoS ONE, Vol. 6, Issue 6, pp. e21118, 2011 (PubMed).

Lo Monaco, Tremante, Cerboni, Melucci, Sibilio, Zingoni, Nicotra, Natali, Giacomini: "Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells." in: Neoplasia (New York, N.Y.), Vol. 13, Issue 9, pp. 822-30, 2011 (PubMed).

Soni, Karande: "Glycodelin A suppresses the cytolytic activity of CD8+ T lymphocytes." in: Molecular immunology, Vol. 47, Issue 15, pp. 2458-66, 2010 (PubMed).

Das, Long: "Lytic granule polarization, rather than degranulation, is the preferred target of inhibitory receptors in NK cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 185, Issue 8, pp. 4698-704, 2010 (PubMed).

Palmisano, Contardi, Morabito, Gargaglione, Ferrara, Pistillo: "HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines." in: Human immunology, Vol. 66, Issue 1, pp. 1-12, 2004 (PubMed).